Together, these results indicate that LMO7-mediated MGMT degradation increases TMZ sensitivity in NSCLC, positioning LMO7 as a potential prognostic biomarker and therapeutic target. The gene discussed is LMO7; the disease is non-small cell lung carcinoma.